- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01287481
Pain and Stress Management for Fibromyalgia
15 marzo 2016 aggiornato da: Mark A. Lumley, Wayne State University
Emotional Exposure and Cognitive Behavioral Therapies for Fibromyalgia
This interventional, randomized controlled study seeks to test the effects of an innovative emotional exposure and processing treatment that targets stress resolution, by comparing it with cognitive-behavioral therapy and a Fibromyalgia education comparison condition.
The investigators also will test proposed mediators of the intervention, including improved autonomic regulation, and explore which subgroups of patients benefit the most from each approach.
Panoramica dello studio
Stato
Completato
Condizioni
Intervento / Trattamento
Tipo di studio
Interventistico
Iscrizione (Effettivo)
230
Fase
- Fase 2
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Luoghi di studio
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48106
- University of Michigan Medical Center
-
Detroit, Michigan, Stati Uniti, 48202
- Wayne State University
-
Southfield, Michigan, Stati Uniti, 48075
- St. John Providence Hospital
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
Da 18 anni a 75 anni (Adulto, Adulto più anziano)
Accetta volontari sani
No
Sessi ammissibili allo studio
Tutto
Descrizione
Inclusion Criteria:
Meet Fibromyalgia (FM) criteria of the American College of Rheumatology (ACR)either:
- 1990 ACR criteria including tender points
- 2010 ACR modified clinical criteria that does not include tender points
Exclusion Criteria:
- Co-morbid autoimmune disorders, including rheumatoid arthritis and systemic lupus
- Other serious medical conditions that can impair health status independent of FM
- Current psychotic disorders (schizophrenia, bipolar disorder, etc.),dissociative identity (multiple personality) disorder, active suicide risk
- Alcohol/drug dependence in past 2 years
- Cognitive impairment or dementia
- Currently have pending (or recently received - within 2 years) FM pain related disability or workman's compensation
- Unable to fluently read or converse in English
- Planning to move from the area in the next 14 months
- Judgment of principle investigator as not appropriate for this trial or all intervention arms
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Stress and Emotions
Seeks to reduce stress and physical symptoms by helping individual become aware of their emotions, express them, and resolve emotional difficulties.
It will use techniques such as writing about stress, role playing how to handle difficult relationships, recognizing and expressing anger and other feelings, and being more open with others.
|
Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.
|
|
Comparatore attivo: Thoughts and Behaviors
Seeks to help individuals function better and improve symptoms by teaching various cognitive and behavioral skills to manage symptoms of fibromyalgia.
It will use techniques such as relaxation training, engaging in pleasant activities, pacing yourself, and changing unhelpful ways of thinking.
|
Focus on cognitive and behavioral skills, such as relaxation, increasing pleasant activities, pacing, and changing ways of thinking.
|
|
Comparatore attivo: Brain and Body
Seeks to help individuals improve health by educating about fibromyalgia so that one can better understand and more effectively communicate about their health.
It will explain the latest scientific information about fibromyalgia, including its causes, the role of the nervous system and body, various medical and alternative treatments, and how to understand research findings.
|
Focus on the empowering patients by providing the latest scientific information about fibromyalgia, including causes, the role of the nervous system, and various treatments.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Brief Pain Inventory
Lasso di tempo: Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
|
Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
SF-12
Lasso di tempo: Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
|
Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
|
|
PROMIS Fatigue short form
Lasso di tempo: Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
|
Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
|
|
Pittsburgh Sleep Quality Index
Lasso di tempo: Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
|
Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
|
|
Center for Epidemiological Studies - Depression Scale
Lasso di tempo: Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
|
Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
|
|
Generalized Anxiety Disorder - 7
Lasso di tempo: Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
|
Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
|
|
Positive and Negative Affect Schedule
Lasso di tempo: Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
|
Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
|
|
Satisfaction with Life Scale
Lasso di tempo: Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
|
Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
|
|
Multiple Ability Self-Report Questionnaire
Lasso di tempo: Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
|
Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
|
|
Patient Global Assessment of Change
Lasso di tempo: Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
|
Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
|
|
Health Care Utilization Scale
Lasso di tempo: Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
|
Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
|
|
Real-time Physical Activity (Actiwatch)
Lasso di tempo: Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
|
Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
|
|
Heart Rate Variability
Lasso di tempo: Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
|
Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
|
|
Levels of Emotional Awareness Scale
Lasso di tempo: Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
|
Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
|
|
Emotional Expressivity Scale
Lasso di tempo: Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
|
Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
|
|
Ambivalence over Emotional Expression
Lasso di tempo: Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
|
Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
|
|
Toronto Alexithymia Scale-20
Lasso di tempo: Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
|
Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
|
|
Impact of Events Scale - Revised
Lasso di tempo: Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
|
Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
|
|
BBCA - short form
Lasso di tempo: Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
|
Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
|
|
Pain Catastrophizing
Lasso di tempo: Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
|
Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
|
|
Beliefs in Pain Control Questionnaire
Lasso di tempo: Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
|
Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
|
|
Communication Thoughts and Feelings Questionnaire
Lasso di tempo: Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
|
Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
|
|
Experimental (thumb nail pressure) threshold and tolerance ratings
Lasso di tempo: Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
|
Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
|
|
2010 ACR modified clinical criteria for FM, including widespread pain index
Lasso di tempo: Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
|
Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Investigatori
- Investigatore principale: Mark A Lumley, Ph.D., Wayne State University
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio
1 maggio 2011
Completamento primario (Effettivo)
1 luglio 2015
Completamento dello studio (Effettivo)
1 luglio 2015
Date di iscrizione allo studio
Primo inviato
2 novembre 2010
Primo inviato che soddisfa i criteri di controllo qualità
28 gennaio 2011
Primo Inserito (Stima)
1 febbraio 2011
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
17 marzo 2016
Ultimo aggiornamento inviato che soddisfa i criteri QC
15 marzo 2016
Ultimo verificato
1 marzo 2016
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 1R01AR057808 (Sovvenzione/contratto NIH degli Stati Uniti)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Stress and Emotions
-
Joint Shantou International Eye Center of Shantou...CompletatoRetinopatia diabetica | Malattia Retinica DiabeticaCina
-
Dr. Faizan AwanCompletatoCovid19 | Stress occupazionaleRegno Unito
-
Human Development Research Foundation, PakistanUniversity of Liverpool; Institute of Psychiatry, WHO Collaborating Center for...CompletatoDepressione | Ansia | Disagio psicologico | Problema emotivoPakistan
-
The University of Hong KongReclutamentoBPSD (Sintomi comportamentali e psicologici della demenza) | Emozione espressa | Sintomo depressivo | Stress da accudimentoHong Kong
-
Xuanwu Hospital, BeijingReclutamentoSonno | Epilessia refrattariaCina
-
Center for Clinical Research and PreventionUniversity of Copenhagen; Slagelse SygehusNon ancora reclutamentoDepressione, Ansia | Intervento | Studio controllato randomizzato
-
Dalarna UniversityUppsala University; The Swedish Research CouncilReclutamentoDemenza | Compromissione cognitiva lieve | Demenza, mista | Demenza di tipo Alzheimer | Compromissione cognitiva soggettiva | Demenza senileSvezia
-
Institut du Cancer de Montpellier - Val d'AurelleUniversity Hospital, Clermont-Ferrand; Laboratoire EPSYLON; Academic resource center...Completato
-
VU University of AmsterdamCompletatoNon stiamo studiando una malattia o una condizione | Lo studio è focalizzato su persone con limitata alfabetizzazione sanitariaOlanda
-
Bournemouth UniversityRoyal Bournemouth and Christchurch Hospitals NHS Foundation TrustCompletatoEffetto della formazioneRegno Unito